Arcturus Faces Major Setbacks: CSL Write-Down, FDA Delay for KOSTAIVE, and Revenue Decline

summarizeSummary

Arcturus Therapeutics reported a significant decline in revenue and increased cash burn for fiscal year 2025, alongside a major $430 million write-down by its partner CSL Seqirus on their collaboration assets and an indefinite delay in the U.S. FDA Biologics License Application for its COVID-19 vaccine, KOSTAIVE.

check_boxKey Events · Earnings and Guidance · ARCT

• Significant Revenue Decline and Increased Cash Burn

  Total revenue decreased by 46% to $82.031 million in 2025 from $152.310 million in 2024. Net cash used in operating activities increased to $74.271 million in 2025 from $59.747 million in 2024, indicating increased cash burn.

• Partner CSL Reports $430M Write-Down on Collaboration Assets

  CSL Limited reported a $430 million accounting write-down attributable to its collaboration agreement with Arcturus, citing declining COVID-19 disease burden and more onerous U.S. regulatory requirements. This suggests a significant devaluation of the vaccine assets by the partner.

• U.S. FDA Indefinitely Delays KOSTAIVE BLA Submission

  The FDA requested an indefinite delay in the Biologics License Application (BLA) submission for the COVID-19 vaccine KOSTAIVE, requiring additional clinical endpoint efficacy study data to align with revised regulatory frameworks.

• International KOSTAIVE Approvals and Weak Japan Sales

  KOSTAIVE received marketing authorization in the European Union (February 2025) and the United Kingdom (January 2026), following its commercial launch in Japan in October 2024. However, the company noted that demand for KOSTAIVE in Japan has been weak, and future sales may decrease.

auto_awesomeAnalysis · ARCT · Life Sciences

This 10-K reveals significant headwinds for Arcturus Therapeutics, primarily stemming from its crucial vaccine collaboration with CSL Seqirus. The $430 million accounting write-down by CSL, representing a substantial portion of Arcturus's market capitalization, signals a severe devaluation of the vaccine assets by its partner. Compounding this is the indefinite delay of the U.S. FDA Biologics License Application (BLA) for KOSTAIVE, which effectively blocks access to the largest vaccine market and raises serious questions about the commercial viability of their lead vaccine candidate. The substantial decline in revenue and increased cash burn further underscore the financial challenges. While the company reported positive clinical progress for its rare disease therapeutics (ARCT-032 and ARCT-810) and the H5N1 vaccine, and successfully remediated its internal control weakness, these positives are largely overshadowed by the commercial and regulatory setbacks for its primary revenue-generating collaboration. The remaining $188 million under the At-The-Market (ATM) program indicates a likely path for future dilution to fund operations, especially given the ongoing losses and need for additional capital. Investors should closely monitor the CSL collaboration, the path forward for KOSTAIVE in the U.S., and the company's cash runway.